Amneal Pharmaceuticals, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $72.1M | $-116.9M | $-84.0M | $-270.6M | $13.2M | $67.8M | $-603.6M | $-19.7M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | $57.3M | $62.6M | $66.2M | $68.1M | $60.7M | $60.4M | $63.3M | $64.4M |
| Amortization | $166.3M | $173.6M | $163.2M | $172.1M | $172.7M | $175.0M | $144.0M | $144.0M |
| Stock-Based Compensation | $32.0M | $27.8M | $26.8M | $31.8M | $28.4M | $20.8M | $21.7M | $167.6M |
| Net Cash from Operating Activities | $340.0M | $295.1M | $345.6M | $65.1M | $241.8M | $379.0M | $1.7M | $250.2M |
| Investing Activities | ||||||||
| Capital Expenditures | $70.1M | $51.9M | $43.2M | $46.4M | $47.7M | $56.4M | $47.2M | $83.1M |
| Business Acquisitions | — | $0 | $0 | $84.7M | $146.5M | $251.4M | $0 | $324.6M |
| Net Cash from Investing Activities | $-112.3M | $-63.0M | $-69.2M | $-174.3M | $-194.2M | $-317.5M | $-19.6M | $-396.4M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | $0 | $0 | $183.0M |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $-31.5M | $-211.8M | $-212.6M | $-106.6M | $-138.1M | $131.8M | $-45.8M | $287.7M |
| Net Change in Cash | $194.5M | $19.3M | $63.9M | $-221.5M | $-90.4M | $194.3M | $-66.0M | $140.9M |
| Free Cash Flow | $269.9M | $243.2M | $302.4M | $18.7M | $194.1M | $322.6M | $-45.5M | $167.1M |